Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Safety and Efficacy Study of ALZT-OP1a as Adjuvant Treatment in Subjects With Post-Ischemic Stroke Cognitive Impairment (PSCI)

NCT03202147 is registered in ClinicalTrials.gov with AZTherapies, Inc. as lead sponsor.

NCT NCT03202147
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03202147 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Safety and Efficacy Study of ALZT-OP1a as Adjuvant Treatment in Subjects With Post-Ischemic Stroke Cognitive Impairment (PSCI)
Lead sponsor
AZTherapies, Inc.
Phase
Phase 2
Overall status
Withdrawn
Start date
December 31, 2023
Completion date
December 31, 2024
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ischemic stroke, post-stroke cognitive impairment